The Use of Prophylactic Antibiotics In the Management of Dog Bites
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00185939 |
Recruitment Status :
Completed
First Posted : September 16, 2005
Last Update Posted : December 5, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This double blinded RCT will help to ascertain the usefulness of prophylactic antibiotics in the management of uncomplicated dog bites, utilizing currently best available antibiotics (Augmentin) and an important clinical outcome of infection.
By enrolling 100-150 patients in this pilot trial as part of a k-award the investigators plan to utilize the point estimates of infection, side effects and other important outcomes and incorporate these into a cost most to determine the most cost effective management of these wounds and to determine if further study is warranted based on the findings.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bite Wound Infection | Drug: Augmentin | Phase 2 Phase 3 |
This double blinded RCT will help to ascertain the usefulness of prophylactic antibiotics in the management of uncomplicated dog bites, utilizing currently best available antibiotics (Augmentin) and an important clinical outcome of infection.
By enrolling 100-150 patients in this pilot trial as part of a k-award the investigators plan to utilize the point estimates of infection, side effects and other important outcomes and incorporate these into a cost most to determine the most cost effective management of these wounds and to determine if further study is warranted based on the findings.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 125 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double |
Primary Purpose: | Prevention |
Study Start Date : | August 2003 |
Study Completion Date : | November 2005 |
- Wound infection
- side effects of medication

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All patients including all children and English speaking/reading persons who present with a full thickness dog bite to participating emergency departments will be considered. Non-English speaking/reading subjects for whom we can provide translation for will also be considered.
Exclusion Criteria:
Exclusion Criteria:
- allergy to penicillin or amoxicillin/clavulanic acid
- wounds presenting with an active infection (require antibiotics) or greater than 12 hours old.
- patients with underlying fracture, joint or neurovascular injury, or multiple trauma requiring specialty referral. Specifically any broken skin over a joint will need treatment and be excluded from the study and randomization.
- patients on immunosuppressive agents, prolonged chronic steroid use (defined as continuous use for > 14 days, 3 times a year) active HIV disease (determined by treating physician on history) or splenectomized. (could skew one group and at risk for overwhelming sepsis and death if infected)
- patients unwilling or unable to complete the required follow-up, and those unable to provide a contact phone number

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00185939
United States, California | |
Mills Peninsula Hospital | |
Burlingame, California, United States | |
UCSF Medical Center | |
San Francisco, California, United States, 94143 | |
Stanford University Medical Center | |
Stanford, California, United States, 94305 |
Principal Investigator: | James V Quinn, MD MS | Stanford University |
ClinicalTrials.gov Identifier: | NCT00185939 |
Other Study ID Numbers: |
K23AR002137 ( U.S. NIH Grant/Contract ) |
First Posted: | September 16, 2005 Key Record Dates |
Last Update Posted: | December 5, 2006 |
Last Verified: | December 2006 |
dog bites infection prophylactic antibiotics cost effectiveness |
Infections Amoxicillin-Potassium Clavulanate Combination Anti-Bacterial Agents Anti-Infective Agents |
beta-Lactamase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |